INOVIQ’s goal is to develop a portfolio of EXO-NET capture tools and EXO-NET powered exosome-based diagnostics for detection of cancer and other diseases. INOVIQ is engaging with key opinion leaders focused on exosome research to establish research collaborations for the development of more accurate and reliable exosome-based diagnostics. The Company expects to advance new EXO-NET collaborations with key opinion leaders for exosome-based diagnostics for other cancers and diseases over the next 12-months. EXO-NET portfolio expansion INOVIQ progressed its research programs to develop new EXO-NET products including: 1) TEXO-NET for isolation of tumour-derived exosomes, and 2) NEURO-NET for isolation of brain-derived exosomes. A patent application for TEXO-NET has been lodged, and NEURO-NET data is being finalised for submission of a new patent application before publication of data to the scientific community. These products are expected to underpin future partnering opportunities for clinical diagnostics, clinical trial assays and companion diagnostics for Oncology and Neurology indications. EXO-NET services Development of a High-Throughput (HT) EXO-NET isolation system to process up to 200,000 samples per year in a clinical laboratory was successfully completed in collaboration with Promega Corporation. INOVIQ now has the capability to offer HT exosome isolation, biomarker discovery and diagnostics development services to Academic and Industry customers from its Australian laboratory. This is expected to provide potential EXO-NET service revenue to the Company, and potentially lead to future partnering agreements for exosome diagnostics. Exosome diagnostics The EXO-Ovarian Cancer test is an exosome-based multi-marker test in development for early detection of ovarian cancer in asymptomatic women. EXO-NET is being used to enable exosome isolation, biomarker discovery and translation of this novel exosomal test from bench-to-clinic to help save women’s lives. Previous proof-of-concept case-control studies performed by The University of Queensland (UQ) demonstrated its exosome-based ovarian cancer test (EXO-OC test) was over 90% accurate for the detection of early-stage ovarian cancer in 450 plasma samples (ASX: 28 July 2021). INOVIQ has secured the option for an exclusive worldwide license to develop and commercialise UQ’s intellectual property in the EXO-OC test (ASX: 1 April 2022). Additionally, UQ has been awarded a $2.7m Medical Research Future Fund (MRFF) grant for development of the EXO-OC test due to the significant unmet need for earlier detection of ovarian cancer. EXOSOME ISOLATION EV isolation using our EXONET powered, fully-automated, high throughout platform1 BIOMARKER DISCOVERY Biomarker discovery services to identify, evaluate and validate EVbased RNA and Protein biomarkers DIAGNOSTIC DEVELOPMENT EV-based clinical diagnostic, clinical trial assay and companion diagnostic development CUSTOMISED EXO-NET TOOLS Design custom EXO-NET tools using ligands for specific EV populations 15 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3